Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer’s drug
Eli Lilly has remunerated USD 81 million upfront for the global rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease. The agreement provides Lilly ownership of a small molecule that has prevented tau aggregation in preclinical models. Switzerland based AC Immune’s tau program has sought to discover and develop small molecules that disaggregate tau proteins and prevent the misfolded proteins from aggregating in the first place. AC Immune targets to decrease pathological tau aggregates and thereby improve the memories of people with Alzheimer’s and other diseases.
Akero Therape...
